Unlock The Disruptive Potential: Analytical Development & Characterization For mRNA

The proven efficacy of mRNA technology as a vaccine against SARS-CoV-2 has driven rapid development, scalability, and flexibility. Its disruptive potential extends beyond prophylactic vaccines to treatments for diseases, such as cancer and immune disorders. MilliporeSigma's assay packages provide the product and process knowledge needed to develop a Quality Target Product Profile (QTPP) and identify the Critical Quality Attributes (CQAs) to unchain the disruptive potential of your mRNA therapy. Download the flyer to learn more about how MilliporeSigma can help you meet your mRNA product’s specific needs.